How many drugs treat Neuroblastoma?

Drug Landscape tracks 10 marketed treatments for Neuroblastoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/neuroblastoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Neuroblastoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neuroblastoma (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Neuroblastoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Hu3F8	NAXITAMAB	Y-Mabs Therapeutics Inc	Glycolipid Disialoganglioside-directed Antibody [EPC]		2020-01-01
Ch14.18	DINUTUXIMAB	United Therap	Glycolipid Disialoganglioside-directed Antibody [EPC]	GD2	2015-01-01
Doxorubicin Hydrochloride	doxorubicin	Pfizer	Anthracycline Topoisomerase Inhibitor	Aurora kinase A	1974-01-01
Liposomal Doxorubicin	liposomal-doxorubicin	Pfizer	doxorubicin	72 kDa type IV collagenase	1974-01-01
Oncovin	Vincristine Sulfate	Pfizer Inc.	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Oncovin	vincristine	Pfizer Inc.	Vinca Alkaloid	Canalicular multispecific organic anion transporter 1	1963-01-01
Cytoxan (Lyophilized)	CYCLOPHOSPHAMIDE	Baxter	cyclophosphamide	Cytochrome P450 3A4	1959-01-01
Busulfex	busulfan	Waylis	Alkylating Drug [EPC]	Matrix metalloproteinase-9	1954-01-01
Adriamycin	Adriamycin	Johann Wolfgang Goethe University Hospital		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
DANYELZA	NAXITAMAB-GQGK	Y-MABS THERAPEUTICS INC	Glycolipid Disialoganglioside-directed Antibody [EPC]	GD2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pfizer · 2 drugs in Neuroblastoma
University of Colorado, Denver · 2 drugs in Neuroblastoma
Pfizer Inc. · 2 drugs in Neuroblastoma
Baxter · 2 drugs in Neuroblastoma
United Therap · 1 drug in Neuroblastoma
University of Birmingham · 1 drug in Neuroblastoma
Waylis · 1 drug in Neuroblastoma
Weill Medical College of Cornell University · 1 drug in Neuroblastoma
Y-MABS THERAPEUTICS INC · 1 drug in Neuroblastoma
Y-Mabs Therapeutics Inc · 1 drug in Neuroblastoma
Zhejiang University · 1 drug in Neuroblastoma
Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 drug in Neuroblastoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Neuroblastoma:

Cite this brief

Drug Landscape (2026). Neuroblastoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/neuroblastoma. Accessed 2026-06-10.

Neuroblastoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing